Genentech Xenon MRI Idiopathic Pulmonary Fibrosis

Last updated: July 1, 2025
Sponsor: Duke University
Overall Status: Active - Not Recruiting

Phase

2

Condition

Scar Tissue

Cystic Fibrosis

Lung Injury

Treatment

Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment

Clinical Study ID

NCT04071769
Pro00101911
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is being done to determine whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments.

Subjects will undergo an approximately hour long comprehensive MRI protocol, including administration of multiple doses of hyper-polarized 129 Xenon. The subjects will have this initial study prior to initiation of IPF therapies. Then the subjects will have repeat studies at 3, 6 and 12 months following the initiation of therapy. Additional studies including pulmonary function studies, serum for bio markers, 6 minute walk distance and a high-resolution computed tomography (HRCT) scan (only at the 6 month visit) will be performed to determine how 129 Xenon MRI performs relative to standard of care evaluations for IPF.

The MRI uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. Risks of the xenon gas are slight numbness in legs, nausea, a feeling of well-being, and mild tingling in fingertips. You will have pulmonary function testing for the study, you may experience breathlessness or dizziness during or immediately following these tests.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Outpatients of either gender, age > 18.

  • Willing and able to give informed consent and adhere to visit/protocol schedules.

(Consent must be given before any study procedures are performed)

  • Clinical diagnosis of IPF by confirmed by multidisciplinary diagnosis and naïve totreatment with an approved IPF therapy (either nintedanib or pirfenidone)

Exclusion

Exclusion Criteria:

  • Subject is less than 18 years old

  • Subjects who have been previously on either pirfenidone or nintedanib

  • MRI is contraindicated based on responses to MRI screening questionnaire

  • Subject is pregnant or lactating

  • Resting oxygen saturation on room air <90% on supplemental oxygen

  • Respiratory illness of a bacterial or viral etiology within 30 days of MRI

  • Subject with ventricular cardiac arrhythmia in the past 30 days.

  • Subject has history of cardiac arrest within the last year

  • Subject does not fit into 129 Xenon vest coil used for MRI

  • Subject deemed unlikely to be able to comply with instructions during imaging

  • Recent exacerbation (within 30 days) defined by the need for antibiotics and/orsystemic steroids

  • Medical or psychological conditions which, in the opinion of the investigator, mightcreate undue risk to the subject or interfere with the subject's ability to complywith the protocol requirements

Study Design

Total Participants: 34
Treatment Group(s): 1
Primary Treatment: Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
Phase: 2
Study Start date:
August 03, 2020
Estimated Completion Date:
September 30, 2029

Connect with a study center

  • Duke University Medical Center

    Durham, North Carolina 27710
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.